IA
AGRX

IFP Advisors’s Agile Therapeutics AGRX Stock Holding History

IFP Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$5K – 3531
2021
Q3 		$5K Hold
3
– – ﹤0.01% 2591
2021
Q2 		$7K Hold
3
– – ﹤0.01% 2372
2021
Q1 		$10K Hold
3
– – ﹤0.01% 2153
2020
Q4 		$14K Hold
3
– – ﹤0.01% 1941
2020
Q3 		$15K Hold
3
– – ﹤0.01% 1767
2020
Q2 		$14K Hold
3
– – ﹤0.01% 1710
2020
Q1 		$10K Hold
3
– – ﹤0.01% 1798
2019
Q4 		$12K Buy
+3
New +$10.5K ﹤0.01% 1860
2018
Q2 		– Sell
-2
Closed -$9K – 4114
2018
Q1 		$9K Hold
2
– – ﹤0.01% 2873
2017
Q4 		$9K Buy
+2
New +$18.6K ﹤0.01% 2918
2017
Q1 		– Sell
-1
Closed -$10K – 4181
2016
Q4 		$10K Buy
+1
New +$14K ﹤0.01% 2928

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IFP Advisors's AGRX Position: Q4 2021 in Review

IFP Advisors sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 3 shares — an estimated $5K sold.

IFP Advisors first reported a position in AGRX in Q4 2016 and held it in 11 quarters. The position peaked at $15K in Q3 2020. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • IFP Advisors reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • IFP Advisors sold 3 Agile Therapeutics shares in Q4 2021, an estimated $5K.
  • IFP Advisors first reported a position in Agile Therapeutics in Q4 2016 and held it in 11 quarters.
  • IFP Advisors's Agile Therapeutics position peaked at $15K in Q3 2020.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on IFP Advisors's 13F filing for Q4 2021, filed 12 Jan 2022.